U.S. flag

An official website of the United States government

NM_007194.4(CHEK2):c.444+1G>A AND TUMOR PREDISPOSITION SYNDROME 4, BREAST/PROSTATE

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Nov 1, 2006
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003333693.1

Allele description [Variation Report for NM_007194.4(CHEK2):c.444+1G>A]

NM_007194.4(CHEK2):c.444+1G>A

Gene:
CHEK2:checkpoint kinase 2 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
22q12.1
Genomic location:
Preferred name:
NM_007194.4(CHEK2):c.444+1G>A
Other names:
IVS3+1G>A
HGVS:
  • NC_000022.11:g.28725242C>T
  • NG_008150.2:g.21625G>A
  • NM_001005735.2:c.573+1G>A
  • NM_001257387.2:c.-334+1G>A
  • NM_001349956.2:c.444+1G>A
  • NM_007194.4:c.444+1G>AMANE SELECT
  • NM_145862.2:c.444+1G>A
  • LRG_302t1:c.444+1G>A
  • LRG_302:g.21625G>A
  • NC_000022.10:g.29121230C>T
  • NM_001005735.1:c.573+1G>A
  • NM_007194.3:c.444+1G>A
Note:
NCBI staff provided an HGVS expression for allelic variant 604373.0013 by confirming that the allele introduced an Hpy188 III site in the product of primers Ch2/3f and Ch2/3r Cybulski et al.,2004 (PubMed 15492928).
Nucleotide change:
IVS2DS, G-A, +1
Links:
OMIM: 604373.0013; dbSNP: rs121908698
NCBI 1000 Genomes Browser:
rs121908698
Molecular consequence:
  • NM_001005735.2:c.573+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_001257387.2:c.-334+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_001349956.2:c.444+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_007194.4:c.444+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
  • NM_145862.2:c.444+1G>A - splice donor variant - [Sequence Ontology: SO:0001575]
Functional consequence:
sequence variant affecting splice donor [Sequence Ontology: SO:1000072]

Condition(s)

Name:
TUMOR PREDISPOSITION SYNDROME 4, BREAST/PROSTATE
Identifiers:

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000026133OMIM
no assertion criteria provided
Pathogenic
(Nov 1, 2006)
germlineliterature only

PubMed (2)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenot providednot providednot providednot providednot providednot providedliterature only

Citations

PubMed

CHEK2 is a multiorgan cancer susceptibility gene.

Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymańska A, Szymańska J, Kurzawski G, Suchy J, Oszurek O, Witek A, et al.

Am J Hum Genet. 2004 Dec;75(6):1131-5. Epub 2004 Oct 18.

PubMed [citation]
PMID:
15492928
PMCID:
PMC1182149

A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.

Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, et al.

J Med Genet. 2006 Nov;43(11):863-6.

PubMed [citation]
PMID:
17085682
PMCID:
PMC2563179

Details of each submission

From OMIM, SCV000026133.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (2)

Description

Cybulski et al. (2004) identified a G-to-A transition in a splice site of exon 2 of the CHEK2 gene (IVS2+1G-A), which results in a 4-bp insertion as a result of abnormal splicing and creates a termination codon in exon 3, in patients with several different types of cancer, including breast and prostate (see TPDS4, 609265)

Cybulski et al. (2006) identified the IVS2+1G-A mutation in 15 (0.8%) of 1,864 Polish men with prostate cancer, 5 (2.0%) of 249 patients with familial prostate cancer, and 22 (0.4%) of 5496 controls. Data analysis yielded an odds ratio of 5.1 for familial prostate cancer in carriers of the splice site mutation. The authors determined that it is a founder mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 24, 2024